Uveal melanomas are the commonest intraocular neoplasm in adults. They pose a serious threat to life with up to 50% of patients ultimately dying as a result of tumour-related disease.1 Those patients who succumb to this disease do so not because of the local effects of the primary tumour, but rather because they develop distant metastases that ultimately critically disrupt the function of the affected organs. It is well recognised that the metastatic potential of uveal melanomas is not uniform: some tumours probably have little or no potential to spread, whereas others readily disseminate. These differences in the biologi cal behaviour of these tumours must, at least in part, reflect differences in the phenotypic properties of the tumour cells. At present, our understanding as to what physiological attributes confer a malignant phenotype on these tumours is ill understood.
Metastases develop as a result of a complex multi step process. Tumour cells must first become motile, invade the local extracellular matrix (ECM), and traverse the blood vessel basement membrane and endothelium. Once in the circulation they must evade destruction by the host's immune system. On reaching a distant site, the tumour cells must cross a blood vessel endothelium and basement membrane before, again, invading the local ECM. Finally, the tumour cells must then be capable of unrestrained replication before tangible deposits develop. This process, which is probably highly inefficient, with only a minute fraction of the liberated cells capable of ultimately producing a viable secondary deposit, has been called the metastatic cascade? The relation ship between the tumour cell and the ECM is vital to the metastatic process. Metastatically competent tumour cells must be capable of forming attachments with elements of the ECM, degrading or digesting it and, perhaps, even secreting new matrix compo nents. 
ROLE OF ADHESION MOLECULES IN METASTATIC DISEASE
The determination of the malignant phenotype is heavily dependent upon the cell surface molecules that mediate cell-matrix (and cell-cell) interactions. Adhesion molecules are a heterogeneous group that mediate contacts between the cell and the ECM and can be divided into at least four main groups based on their molecular structure? These groups are: the integrins, the cell surface proteoglycans, molecules of the immunoglobulin supergene family and lectin-like proteins.
Integrins are the principal receptors on animal cells for binding to most ECM proteins including collagen, fibronectin and laminin. Integrins are transmembrane glycoproteins composed of two chains, alpha and beta, non-covalently associated to form a heterodimeric complex. Approximately 20 integrin heterodimers, made from 14 types of beta subunit and 9 types of alpha subunit, have been defined, and new forms are still being discovered. 4 This diversity is increased further by the alternate splicing of some integrin RNAs. The normal cell expresses a variety of integrins, which will vary depending on the specific function of the cell. Changes in the expression of cell surface molecules including integrins are probably vital to the acquisi tion of the metastatic phenotype.
Integrin expression has been studied extensively in cutaneous melanomas. The results, to date, indicate that normal human cutaneous melanocytes express a limited number of bl and b3 integrins. In contrast, melanoma cells, in vitro and in vivo, can acquire the expression of integrin subunits such as a4, as and a7 which are not normally found on melanocytes. Increased expression of other subunits found on normal melanocytes such as aI, a2, and av may also occur. 5 -9 Moreover, changes in integrin expression in cutaneous melanomas have been observed in the transition from radial to vertical growth phase, with .. . In contrast, integrin expression in uveal melano mas has not been studied extensively. ten Berge et al. 11 examined integrin expression in 32 primary and 4 metastatic uveal melanomas and failed to find any correlation with cell type or invasiveness. Furthermore, they found that the av(33 vitronectin receptor, which is associated with cutaneous mela noma progression, was not expressed in uveal melanoma. Interestingly, they did find low levels of a4 expression in 3 of the 4 metastatic lesions studied; a finding previously noted in cutaneous metastatic melanomas? Creyghton et at. 12 in a study of three cell lines established from uveal melanomas found a V(33 expression in one of them, in contrast to the previous study. Rohrbach et al. 13 failed to find significant expression of the laminin receptor (a6 (31) , an integrin implicated as an index of invasive potential in other carcinomas, in a study of 12 uveal melanomas. It is clear from these preliminary studies that the expression of integrin molecules in uveal melanomas is variable, and a pattern, if it exists, has yet to be established.
UVEAL MELANOMA CELL ADHESION AND ITS INHIBITION IN VITRO
Whilst much work has focused on the role of specific adhesion molecules and their possible role in malignant disease, my own group has investigated ways of inhibiting tumour cell adhesion to the ECM by modulating intracellular signal transduction. In particular, we have investigated the possible role of calmodulin antagonists in inhibiting the attachment of uveal melanoma cells to ECM constituents in vitro.1 4 -16 Communication between cells is a basic prerequi site of all multicellular organisms. Cell signalling requires both extracellular signalling molecules and a complementary set of receptor proteins on each cell that enable them to bind and respond to each other in a characteristic way. G-protein-linked receptors are the largest family of cell-surface receptors and, in the main, these receptors alter the concentration of one or more intracellular signalling molecules. These molecules are often referred to as intracellular mediators or second messengers. In turn, these intracellular molecules pass on their signal by altering the behaviour of specific cellular proteins.
The two most abundant intracellular mediators are cyclic AMP and calcium ions. In the normal cell the resting concentration of free calcium is only between 10-7 and 10-8 molll, and a 10-to 100-fold increase in I. G. RENNIE this concentration initiates the appropriate response. The effect of this increased level of free calcium is propagated further by several specific calcium bind ing proteins, the most important of which is calmodulin. Calmodulin is a ubiquitous intracellular protein, which comprises a single polypeptide chain of about 150 amino acids with four high-affinity calcium binding sites. It undergoes a conformational change when it binds to calcium. This allosteric change activates the calmodulin which, in turn, is then able to activate a wide variety of enzymes, including those regulating nucleotide metabolism.17 In a study of the possible role of signal transduction mechanisms in the acute attachment of murine B16 melanoma cells to ECM proteins, MacNeil et al. 25 found evidence to suggest that intracellular calcium and calmodulin have significant roles in tumour cell attachment. In contrast, manipulation of cyclic AMP did not appear to affect tumour cell attachment. In the light of these findings, we elected to investigate the effect of calmodulin antagonists, in particular tamoxifen, on human uveal melanoma cells in vitro.
Tamoxifen has been used extensively in the treatment of breast cancer and significantly prolongs the disease-free survival and decreases mortality. 1 9 Whilst many of its pharmacological properties are attributable to its anti-oestrogen activity, it also has a significant, albeit lesser effect on patients whose tumours are oestrogen-receptor-negative. Tamoxifen has been used in the treatment of other malignancies, including metastatic cutaneous malignant melanoma, where its effect may not be due to its anti-oestrogen activity.18,2 0 Besides its anti-oestrogen activity, tamoxifen is known to inhibit both calmodulin and protein kinase C21-23 and it is postulated that part of its anti-tumour activity may be mediated via its effect on calmodulin. 1 4 To examine the effects of tamoxifen and another calmodulin antagonist J8 (N-( 6-amino-octyl-5-iodo-1-naphthalene) on uveal melanoma cell attachment to matrix protein, we established short-term cultures (before passage 6) using a previously described technique? 4 Cell attachment was measured in 96-well, flat-bottomed microtitre dishes that were coated with a specific substrate as described by MacNeil et al. 25 Six different cell lines were used and their affinity to attach with a variety of substrates including plastic, type I collagen, type III collagen, type IV collagen, fibronectin, gelatin, RGD, vitronectin and polY-L-lysine was examined to establish a preferred substrate. The cells demonstrated a significant pref erence for collagens type I, III and IV and fibronectin.15,16 The attachment to the substrates was rapid, with cells achieving 90% attachment on fibronectin (the best substrate) and 60% attachment on gelatin (the worst substrate) in 10 minutes. The effect of tamoxifen on tumour cell attachment was then examined using fibronectin as a substrate. A significant reduction in tumour cell attachment was observed. Three of the uveal melanoma cell lines were then used to test the effect of tamoxifen on attachment to the other previously tested substrates. Again, tamoxifen produced a significant reduction in cellular attachment on all the substrates tested.
Manipulation of the cyclic AMP pathway using forskolin to stimulate adenylate cyclase and dideoxy adenosine (DDA) to inhibit it, failed to inhibit tumour cell attachment significantly. Similarly, attempts to modulate protein kinase C activity using phorbol ester PMA (stimulatory) and stauro sporine (inhibitory) did not significantly affect tumour cell adhesion. Alteration of the intracellular calcium levels using either ionomycin, which increases calcium levels, or TMB8 (3,4,5-trimethoxy benzoic acid 8-diethylamino octyl ester), which reduces intracellular calcium, produced a reduction in cell attachment. J8, a known calmodulin antago nist, also produced a reduction in tumour cell attachment. From these results it may be seen that tamoxifen is capable of reducing tumour cell attach ment in vitro and that this effect may be produced by modulation of the calcium/calmodulin pathway.
TUMOUR CELL DEGRADATION OF THE ECM: THE ROLES OF PROTEASES
Besides adhering to the ECM, tumour cells must be capable of degrading elements of the ECM, including basement membrane, to gain access to the circulatory system. To effect this process, tumour cells are capable of producing a wide range of proteolytic enzymes, including plasminogen activators, metallo proteinases and cathepsins. 26,27 Two types of plasmi nogen activator are known to exist: tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Both forms are cap able of converting plasminogen to the active serine protease -plasmin; and both these enzymes may have a significant role in the metastatic process by promoting the degradation of ECM componentsP Studies using tumour animal models have shown that the use of antibodies against uP A can either inhibit or reduce the incidence of metastases28,29 and an in vitro study using the MeWo human melanoma cell line, which only produces tP A in culture, found that invasion through a variety of matrices was reduced in the presence of an anti-tPA antibody?O Investigations into the possible role of plasmino gen activators in ocular melanomas are limited. Cottam et al. 31 examined human uveal melanoma cell lines for fibrinolytic activity and found it to be present in 9 of the 10 lines studied. Moreover, they found that the highest level of fibrinolysis was present in the cell lines derived from patients with tumours where significant scleral invasion was 241 observed. Recently, Alizadeh et al. 27 have investi gated the role of tissue-type plasminogen activator in the metastasis of murine intraocular melanomas. They used two B16 murine melanoma cell lines: the D5.1G4 1ine which is known to produce low levels of tP A and has a low level of metastatic activity, and the Queen's line which, in contrast, produces a high level of tP A activity and is known to be highly metastatic. The D5.1G4 line was transfected with a full length of cDNA encoding for human tP A. The Queen's line was transfected with a cDNA which codes for human plasminogen activator inhibitor type 1 (PAI-1). Both transfected and non-transfected cell lines were then inoculated either intravenously or intracamerally into mice which were subsequently killed. The number of pulmonary metastases in each group was determined and it was found that D5.1G4-injected transfected cells produced extensive pulmonary metastases, whilst inoculation with the non-trans fected controls did not. In contrast, the transfected Queen's cell line, when injected intravenously, had a significantly reduced metastatic potential compared with the non-transfected controls. Furthermore, the transfected Queen's melanoma cells failed to pro duce metastases when inoculated intracamerally, whilst the non-transfected cells produced extensive pulmonary deposits. However, intracameral inocula tion of the tPA-transfected D5.1G4 cell line did not result in the production of pulmonary metastases. Whilst the results of these experiments are slightly conflicting they do suggest that tP A is involved in the metastasis of murine intraocular melanomas.
Matrix metalloproteinases (MMPs) are a group of enzymes that are involved in normal remodelling processes including embryonic development, post partum involution and wound healing. They are implicated in a number of pathological processes including rheumatoid arthritis, peridontitis and tumour cell invasion. Enzymes within this group can be distinguished by a number of properties, including a putative zinc binding site, secretion in a zymogen form, cleavage of the enzyme during activation resulting in the loss of approximately 10 kDa, cleavage of ECM components by the enzyme and inhibition by tissue inhibitors of metalloproteinases (TIMPs)?6 Five subgroups have been designated, and of these the type IV metallo proteinases (gelatinases) have been widely impli cated in tumour cell invasion and metastases?6 In particular, it has been proposed that secretion of a 92 kDa species of gelatinase (MMP-9) by carcinoma or oncogene-transfected cells correlates with an increased metastatic potentia1. 26 Cottam et al. 31 have investigated the secretion of matrix metallo proteinases in 15 human uveal melanoma lines. They found that all the cell lines secreted a 72 kDa gelatinase (MMP-2) and, in addition, nine of the lines secreted a 92 kDa gelatinase (MMP-9). The clinical significance of these results has yet to be elucidated.
CONCLUSIONS
The dissemination of tumour cells from the eye of a patient with a uveal melanoma to form metastatic deposits in a distant organ is a complex and, probably, highly inefficient multi-step process. To make this journey, the successful tumour cells must be capable of interacting with the ECM of the host. Our understanding of this relationship is, at present, incomplete. The acquisition of this knowledge may allow us to develop new strategies in the fight against this uncommon, but potentially devastating disease.
